Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Rivertop Renewables Begins Contract Manufacturing to Scale-Up Green Chemicals

Published: Tuesday, April 02, 2013
Last Updated: Tuesday, April 02, 2013
Bookmark and Share
Demonstrated capability of breakthrough oxidation technology enables commercial-scale products and advanced testing.

Rivertop Renewables (, a Montana-based renewable chemicals company, today announced it has successfully scaled its patented process technology from the lab to pilot manufacturing. Rivertop has contracted with DTI (, a custom manufacturer of fine and specialty chemical products based in Danville, Virginia, to pilot the manufacture of Rivertop's sustainable, high performing, cost-competitive, glucarate-based products. Product made in this initial phase of contract manufacturing will be used to fulfill Rivertop's commercial contracts for bio-based corrosion inhibitors. Remaining volumes of manufactured product will be used by the company and its customers to develop and test glucarate applications in a myriad of other industrial and consumer markets.

"Demonstrating the capability of our technology is another key milestone for our company and proof point for our oxidation process," said Jere Kolstad, President of Rivertop. "Contract manufacturing is a critical step along the way to a capital-efficient technology deployment strategy that yields a high return on investment."

Commencing in February 2012, Rivertop's pilot manufacturing has produced numerous batches of glucarate-based products at approximately 850 pounds per run. DTI's unique manufacturing technologies and flexibility enabled the accurate scaling of Rivertop's platform oxidation process. Data derived from these and subsequent runs will enable Rivertop and DTI to scale to a capacity up to 10 million pounds of contract-manufactured product per year. This next scale of production is projected to come online in the fourth quarter of 2012.

"The DTI team is excited to see and support the Rivertop team in reaching another key milestone in their business strategy," said Tim Condron, CEO of DTI. "Both teams worked tirelessly and collaboratively to meet an aggressive project timeline to transition the Rivertop technology from the lab to a manufacturing environment. This is an exciting time for the Rivertop team and we are positive the market will respond well to this new technology."

In addition to starting contract manufacturing, Rivertop is currently undergoing a multi-million dollar expansion of its research and development laboratories, including the construction of a semi-works facility, at its headquarters in Missoula, Montana. Successful contract manufacturing combined with the coming semi-works will enable the company to scale directly from pilot to global scale production in the coming years, removing the need for a costly demonstration plant.

The Department of Energy (DOE) has identified glucaric acid as one of the top 12 chemicals of the future made from renewable sources. Rivertop initially plans to use its glucaric acid products as an effective and cost-competitive replacement for phosphates in the multi-billion dollar markets for global detergent builders, as well as corrosion inhibitors and chelants to protect transportation and industrial infrastructure without damaging water quality. Multiple longer-term opportunities exist in the company's research with advanced biodegradable polymers, adhesives, and other functional materials. Rivertop's platform process is capable of utilizing a wide variety of sugars to produce a large spectrum of green chemicals and bio-based products that possess a range of properties with applications in various markets.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos